Results 101 to 110 of about 73,667 (245)

The long-term effectiveness of efavirenz-based combination antiretroviral therapy, the impact of pharmacogenomics and pharmacokinetic interaction of artemisinin-based antimalarial therapy on efavirenz exposure among Ghanaian HIV-infected patients [PDF]

, 2013
Dr. Fred Stephen Sarfo, The long-term effectiveness of efavirenz-based combination antiretroviral therapy, the impact of pharmacogenomics and pharmacokinetic interaction of artemisinin-based antimalarial therapy on efavirenz exposure among Ghanaian HIV ...
SARFO, FRED,STEPHEN
core  

Mechanism and fidelity of HIV reverse transcriptase.

Journal of Biological Chemistry, 1992
We have examined the RNA-dependent and DNA-dependent polymerase and ribonuclease H catalytic activities of human immunodeficiency virus reverse transcriptase using rapid transient kinetic methods with defined synthetic 25/45-mer DNA/RNA and DNA/DNA primer/templates.
W M, Kati, K A, Johnson, L F, Jerva, K S, Anderson   +3 more
openaire   +2 more sources

Long‐Acting Cabotegravir/Rilpivirine Reduces Immune‐Activation and ‐Senescence in People With HIV With CMV Co‐Infection

Immunology, Volume 179, Issue 1, Page 138-148, September 2026.
This study investigates the impact of switching to long‐acting (LA) injectable cabotegravir and rilpivirine (CAB/RPV‐LA) on immune‐activation and ‐senescence in people with HIV (PWH). Thirty‐seven PWH switching to CAB/RPV‐LA and nine continuing oral ART were analysed over 72 weeks. LA therapy led to significant reductions in activation T and senescence
Mariasilvia Guardiani, Eeva Tortellini, Anna Carraro, Maria Antonella Zingaropoli, Lorenzo Ansaldo, Alessandra Grimaldi, Serena Vita, Federica Dominelli, Fabio Mengoni, Caterina Pasquazzi, Ombretta Turriziani, Maria Rosa Ciardi, Vincenzo Vullo, Claudio Maria Mastroianni, Raffaella Marocco, Cosmo Del Borgo, Miriam Lichtner   +16 more
wiley   +1 more source

HIV Stigma and Missed Medications in HIV-Positive People in Five African Countries. [PDF]

, 2009
The availability of antiretroviral medications has transformed living with HIV infection into a manageable chronic illness, and high levels of adherence are necessary. Stigma has been identified as one reason for missing medication doses.
Dlamini, Priscilla S., Mullan, Joseph, Holzemer, William L., Kohi, Thecla W, Chirwa, M., Wantland, Dean, Makoae, L.N, Naidoo, J., Makoae, Lucy N., Dlamini, Priscilla S, Makoae, Lucy N, Dlamini, P.S, Holzemer, W.L, Uys, L.R, Wantland, D., Greeff, M., Chirwa, Maureen, Mullan, J., Kohi, Thecla W., Naidoo, Joanne, Uys, Leana R, Holzemer, William L, Greeff, Minrie, Uys, Leana R., Kohi, T.W   +24 more
core   +1 more source

Nonradioactive Detection of Retroviral- Associated RNase H Activity in a Microplate-Based, High-Throughput Format

BioTechniques, 2002
None of the available antiretroviral drugs that are currently used in the clinic to treat infection with HIV-1 is directed against the RNase H active site of the reverse transcriptase.
N. McLellan, X. Wei, B. Marchand, M.A. Wainberg, M. Götte   +4 more
doaj   +1 more source

DMS‐MaPseq and DREEM Analyses Implicate the Critical Role of RNA Structural Dynamics in Turnip Yellow Mosaic Virus Pathogenicity

Advanced Science, Volume 13, Issue 43, 3 August 2026.
RNA structural profiling of Turnip Yellow Mosaic Virus by DMS‐MaPseq and DREEM analyses uncover that viral genome‐wide RSS is highly complicated and heterogeneous, with alternative RSSs widely distributed across the genome. Notably, the viral 3’ tRNA‐like structure adopts alternative conformations in vivo.
Jiaying Zhu, Changhao Li, Chisimbily Onyia, Xindi Li, Xingxing Yan, Songxiao Zhong, Taerin Oh, Xiuren Zhang   +7 more
wiley   +1 more source

Erratum: Author correction to 'Approved HIV reverse transcriptase inhibitors in the past decade' [Acta Pharmaceutica Sinica B 12 (2022) 1567-1590]. [PDF]

Acta Pharm Sin B, 2023
Li G, Wang Y, De Clercq E.
europepmc   +1 more source

PrEP at the site of action in cisgender and transgender women: A pharmacology study of blood and rectal CD4+ lymphocytes

British Journal of Clinical Pharmacology, Volume 92, Issue 8, Page 2949-2959, August 2026.
Background Female sex hormones used in feminizing hormone therapy (FHT) may influence activation and persistence of HIV pre‐exposure prophylaxis (PrEP) medications. The clinical relevance of this interaction remains unclear, particularly for transgender and cisgender women (TGW and CGW).
Elizabeth Hastie, Megha Srivasta, Edward R. Cachay, Leah Burke, Sara Gianella, Stephen Rawlings, Frank Z. Stanczyk, Craig Sykes, Angela D. M. Kashuba, Jill Blumenthal, Mackenzie L. Cottrell   +10 more
wiley   +1 more source

Profile of etravirine in the treatment of HIV in pediatrics

Pediatric Health, Medicine and Therapeutics, 2013
Walter Dehority,1 Rolando M Viani2 1Department of Pediatrics, Division of Infectious Diseases, The University of New Mexico Health Sciences Center, University of New Mexico, Albuquerque, NM, USA; 2Department of Pediatrics, Division of Infectious Diseases,
Dehority W, Viani RM
doaj  

Approved HIV reverse transcriptase inhibitors in the past decade. [PDF]

Acta Pharm Sin B, 2022
Li G, Wang Y, De Clercq E.
europepmc   +1 more source